AstraZeneca and Sanofi’s RSV Treatment Approved by China’s Medical Regulators

Beyfortus, an antibody developed by AstraZeneca and Sanofi, has received clearance from the China’s National Medical Products Administration to protect newborns against respiratory syncytial virus. 

Authorisation is grounded on information derived from phase lll clinical studies and a comprehensive clinical research initiative. 

One administration of Beyfortus proved effective in addressing lower respiratory tract infections linked to RSV for a duration of five months. 

Iskra Reic, AstraZeneca’s Vaccines chief officer, commented, “Beyfortus represents the first opportunity to prevent serious respiratory disease due to RSV for all infants in China.” 

Reic went on to add, “The science that Beyfortus is built on demonstrates AstraZeneca’s leadership in addressing the needs of the most vulnerable populations and reducing the infectious disease burden on healthcare systems.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.